BSE filing, NSE: CONCORDBIO. Summary written from the filing by ALFA Finder's alert engine.
Concord Biotech Ltd: key numbers
- Share price
- ₹1,265.60
- Market cap
- ₹13,240 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 46.9×Sector 46.5×
- Promoter holding
- 44.09%+0.01% QoQ
- FII holding
- 7.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Earnings Call Transcript: Key Takeaways
Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.
- Call
- Guides 18% growth
Concord Biotech Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹309.1 Cr (+25%) and PAT ₹69.6 Cr (+10%); H1 revenue ₹566.6 Cr (+26%). Margins compressed; Inspira dermatology division launched.
Concord Biotech Q2 FY27 Results: Net Profit ₹69.6 Cr, Up 10.3% YoY
Concord Biotech Ltd reported revenue from operations of ₹309.1 Cr (+25.1% YoY) and net profit of ₹69.6 Cr (+10.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹69.6 Cr · +10.3% YoY
Concord Biotech Bonus Issue
Concord Biotech's postal ballot approved a bonus issue and an authorised capital increase. No cash is paid and no ratio is stated.
Concord Biotech Board Meeting Date
Concord Biotech has scheduled its Q2 FY27 board meeting for 27 Oct 2026 to approve standalone and consolidated results. Trading window remains closed until 48 hours post result declaration.
Concord Biotech Other Announcement
Concord Biotech Ltd has filed its quarterly shareholding pattern under Regulation 31 for the period ended September 30, 2026.
Other bonus issue announcements
All →Shreeji Global FMCG Bonus Issue
Shreeji Global FMCG board recommended a 1:1 bonus issue funded from securities premium, with no cash paid. Paid-up capital rises from Rs.22.76 Crore to Rs.49.92 Crore.
Anlon Technology Solutions Bonus Issue
Anlon Technology Solutions fixed 02-Nov-2026 as the record date for its 2:5 bonus issue of equity shares. The bonus is free shares from reserves, with no cash paid.
Titan Biotech Bonus Issue
Titan Biotech allotted 1,03,29,625 bonus shares of Rs. 2 each in a 1:4 ratio. Paid-up capital rose to Rs. 10.33 Crore post-allotment.
Utssav CZ Gold Jewels Bonus Issue
Utssav CZ Gold Jewels' board recommended a 1:1 bonus issue from free reserves on 23 October 2026. Paid-up capital rises from Rs.25.00 Crore to Rs.50.00 Crore, subject to AGM/postal ballot on 25 November 2026.
Utssav CZ Gold Jewels Bonus Issue
Utssav CZ Gold Jewels approved a 1:1 bonus issue of 2,49,98,000 shares, subject to shareholder approval. No cash is paid; the shares come from free reserves.
Tech Mahindra Bonus Issue
Tech Mahindra Ltd is seeking shareholder approval via postal ballot for the issuance of bonus equity shares and an increase in its authorised share capital.